[5]Zou W, Wolchok JD, Chen L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Sci Transl Med. 2016;8:328rv4. [6]Zhu Y, Chen M, Xu D, et al...
PD-1主要在激活的T细胞和B细胞中表达,功能是抑制细胞的激活,这是免疫系统的一种正常的自稳机制,因为过度的T/B细胞激活会引起自身免疫病,所以PD-1是我们人体的一道护身符。但是,肿瘤微环境会诱导浸润的T细胞高表达PD-1分子,肿瘤细胞会...
Programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) blockade therapy has become a game-changing therapeutic approach revolutionizing the treatment setting of human malignancies, such as renal cell carcinoma (RCC). Despite the remarkable clinical activity of anti-PD-1 or anti-PD-L1 monoc...
[5]. Gong B, KiyotaniK, Sakata S, et al. Secreted PD-L1 variants mediate resistance to PD-L1blockade therapy in non–small cell lung cancer[J]. Journal of ExperimentalMedicine, 2019, 216(4): 982-1000.[6]. Milhem M,Zakharia Y, Davar D, et al. O85 Durable responses in anti-PD-1...
2021年12月发表于 cell子刊Cancer Cell(IF=31.743)上的“Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer”; PD-1/PD-L1研究联合单细胞测序 在三阴性乳腺癌(TNBC)中,联合化疗和检查点抑制剂的作用机制尚未明确。在本篇文章中,...
Despite chemoradiotherapy and targeted therapy improving clinical outcomes, overall survival remains poor. Immune checkpoint blockade, especially blockade of programmed death-1 (PD-1) receptor and its ligand PD-L1, achieved robust responses and improved survival for patients with locally advanced/metastatic...
脑胶质瘤等中枢神经系统肿瘤是免疫原性较低的“冷肿瘤”,鞘内注射CAR-T有较好的疗效表现,在此基础上联合PD-1抑制剂治疗是否能够进一步提高治疗反应?近日,一项发表于JAMA Oncol的小样本试验表明,静脉注射帕博利珠单抗可有效阻断脑脊液中内源性及过继性T细胞的PD-1。
Comparative efficacy of combined CTLA-4 and PD-1 blockade vs. PD-1 monotherapy in metastatic melanoma: a real-world study ‘Cutting the cable’ between CD8+ T and T regulatory cells enhances checkpoint immunotherapy Acquired resistance to anti-PD1 therapy in patients with NSCLC associates with imm...
Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure) Abstract The emergence of programmed death-ligand 1 (PD-L1)/programmed death-1 (PD-1)-targeted therapy has demonstrated the importance of the PD-L1 : PD-1 ... JM Kim,DS Chen - 《Annals of Oncology》 被引量...
[1]George, S., Miao, D., Demetri, G.D., Adeegbe, D., Rodig, S.J., Shukla, S., Lipschitz, M., Amin-Mansour, A., Raut, C.P., Carter, S.L., et al. (2017). Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyos...